drugset / Trial / NCT07205536
Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective observational study designed to observe and evaluate the safety and efficacy of mecapegfilgrastim in the treatment of moderate-to-severe myelosuppression associated with concurrent chemoradiotherapy. The project will provide more robust evidence-based medical support for the use of long-acting granulocyte-stimulating agents in patients undergoing concurrent chemoradiotherapy.
Timeline
- Start
- 2025-08-01
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mecapegfilgrastim | Protein / enzyme biologic | 100 ug/kg | Subcutaneous |
| Subject | Mecapegfilgrastim | Protein / enzyme biologic | 6 mg | Subcutaneous |
| Comparator | Leucogen | Small molecule | — | — |